Concepedia

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Amer M. Zeidan, Kiyoshi Ando, Odile Beyne Rauzy, Mehmet Turgut, Ming‐Chung Wang, Roberto Cairoli, Hsin‐An Hou, Yok‐Lam Kwong, Montserrat Arnán, Stef Meers,

The Lancet Haematology · 2023 · 67 citations · 19 references

DOI

Concepts

References

19

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

BMJ · 2010 · 8.7K citations · Full text

, , +16

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider et al. · Journal of Clinical Oncology · 2018 · 3.7K citations · Full text

, , +17

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg, Heinz Tuechler, Julie Schanz et al. · Blood · 2012 · 3.1K citations · Full text

, , +12

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian et al. · Blood · 2022 · 2.7K citations · Full text

, , +17

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

, , +9